Stop the treatment leak

0:00
Host A: Well, if you are in pharma senior management, you know you spend billions perfecting the chemistry of your therapies. But then you kind of just pour that perfect science into a leaky bucket.

0:12
Host B: Right. A massively leaky bucket.

0:15
Host A: Yeah, exactly. Because according to the World Health Organization, across chronic diseases, about 50% of your outcomes and revenue leak right out the bottom — just because patients simply stop taking their medications.

0:30
Host B: And to plug that leak, we really have to look at the behavioral triggers causing it. McKinsey's data paints a pretty stark picture here — they found that 50 to 60% of patients drop off their prescribed medications in the very first year.

0:44
Host A: Wow. That is huge. Just year one.

0:47
Host B: Just year one. So in this deep dive, we are using data from the WHO, the CDC, and McKinsey alongside a real-world case study — the StayOnTreatment platform — to understand how to bridge this gap for both chronic brands and vaccines.

1:05
Host A: So why are they dropping off so quickly? Is the burden of treatment just too high for them?

1:10
Host B: It is a combination of things. You have polypharmacy — managing multiple drugs at once — complex regimens, and just the silent nature of some diseases.

1:20
Host A: Meaning if they do not see symptoms, they just forget about it.

1:24
Host B: Right. The urgency fades, and they just stop. And for you, the listener, projecting your brand's financials — fixing this impacts three immediate strategic revenue areas. First, extending overall treatment duration. Second, capturing lost mid-treatment revenue. Our data shows 61% of patients actually enroll in support programs mid-journey, not on day one.

1:48
Host A: Which makes total behavioral sense. They don't enroll on day one because the reality of treatment — daily pill fatigue, side effects — it does not actually hit them until month two or three.

2:00
Host B: Precisely. And the third revenue area is closing HCP behavioral gaps. There is a staggering 137% difference in enrollment velocity between specialists — just based on the doctor. Which tells us that how a doctor introduces a treatment plan matters immensely.

2:18
Host A: I have to push back a bit on the traditional solutions here. Because for years, the industry's answer has just been — let us build a patient support app.

2:26
Host B: Oh, the classic native app. But forcing a chronically ill patient to download a separate health app is like putting a digital toll booth on their road to recovery. They are already exhausted. The toll is just too high.

2:40
Host A: It comes down to cognitive load. An app requires a download, a login, a whole change in daily routine. It is too much work.

2:50
Host B: A platform like StayOnTreatment bypasses all of that. It is entirely app-agnostic — no app stores, no passwords. The patient simply scans a QR code at their doctor's office, taking maybe 30 seconds, and they are enrolled into secure one-way WhatsApp or SMS messaging. A simple text that meets them exactly where their attention already is.

3:12
Host A: And by skipping the native app, you suddenly have massive scalability and reusability across diverse countries and languages.

3:20
Host B: Totally. And for senior management, the year one KPIs on a frictionless system like this are substantial. We are looking at a 1.7 to 2 times extension in treatment duration, a 99.98% program adherence rate, alongside real-time cross-segment enrollment comparisons — so you can see exactly which HCPs are engaging.

3:42
Host A: And this mechanism isn't just for chronic care, is it?

3:45
Host B: Not at all. The CDC validates this exact approach for prevention — simple reminder and recall text programs boost adult vaccine adherence by up to 17%.

3:55
Host A: But wait — scaling an app-free SMS-based system across borders introduces a massive new problem. You are pinging patients on their personal WhatsApps globally. Privacy issue.

4:07
Host B: Yes. The answer is a compliance-first architecture. The platform shares absolutely zero personal data with pharma partners — fully anonymized. It holds ISO 27701 and ISO 9001 certifications, handling data with the same cryptographic security and rigid protocols as a major international bank. And it actually passed multiple strict IT and business ethics pharma audits as recently as November 2025.

4:35
Host A: But how can doctors possibly manage this alongside their crushing daily workload? They do not have time to be IT administrators for a messaging platform.

4:44
Host B: They do not have to be. That 30-second QR scan at the point of care is the entire onboarding process. From there, the platform automatically handles pre-approved, tailored educational messages and reminders, while feeding the doctor anonymized behavioral insights. It is essentially automating the follow-up without adding a single minute to the consultation.

5:08
Host A: Which is the holy grail.

5:10
Host B: Absolutely. Securing a first-mover advantage in adopting compliant, app-agnostic adherence platforms is critical — whether you are managing chronic conditions or driving vaccine uptake. You already have the clinical efficacy. Closing the behavioral gap is the next great frontier in real-world execution.

5:30
Host A: The science is only as good as the patient's willingness to use it. So let us leave you with this to mull over. Think back to that leaky bucket. If your groundbreaking therapy works perfectly in a billion-dollar clinical trial, but fails in the real world simply because a patient lacked a basic text reminder — does the ultimate responsibility for that failed outcome lie with the patient, or with the manufacturer?